Putative risk factors (DNA damage) and risk modifying factors (DNA repair and cell proliferation) were examined in an experimental mouse model in which treatment with dimethylhydrazine (6.8 mg/kg DMH i.p. once weekly) for up to 20 weeks induces colon tumours in a site specific manner with 0, 43 and 87% of animals having proximal, mid and distal colon tumours respectively at the highest cumulative dose. Levels of the pro-carcinogenic DNA adduct, O 6 -methylguanine (O 6 -MeG), in colonic DNA were found to vary with time after final treatment and with location within the colon but not with total DMH dose. O 6 -MeG levels were generally lowest in proximal colon DNA and highest in distal colon DNA. Steady state O 6 -MeG levels were obtained at the highest cumulative DMH dose with O 6 -MeG levels in mid and distal colon DNA being 5 and 10 times higher those in proximal colon DNA. O 6 -alkylguanine-DNA alkyltransferase (MGMT) activity, and cell proliferation indices in the colon were also found to vary with time after final treatment but not with either location within the colon or total DMH dose. O 6 -MeG levels, MGMT activity and cell proliferation indices at specific time points as well as basal MGMT activity were not associated with differences in tumour yield within the colon. However tumour yield was associated with the cumulative amount of O 6 -MeG present in DNA over the treatment period and with the treatment induced cumulative increase in cell proliferation, particularly within regions of the colon crypt where stem cells reside but not with cumulative changes in MGMT activity. Results are consistent with an increased cancer risk arising from an increased mutation load in the target stem cell population due to increased adduct formation/persistence and cell proliferation but also suggest that other cell specific factors may help to determine tumourigenic response.
Introduction
The induction of colon tumours by dimethylhydrazine (DMH) is a widely studied experimental model because of a number Abbreviations: DMH, dimethylhydrazine; O 6 -MeG, O 6 -methylguanine.
© All rights reserved. Oxford University Press 2003 527 of factors including the pronounced organotropic properties of the carcinogen (1), the wide variation in tumour response in different rodent strains (2) (3) (4) (5) , the dietary induced modulation in tumour incidence (6) , the similar distribution of tumours within the human colon and the colon of treated animals (7, 8) and the similarity between animal and human pathology (9) . Implicit in such work is the assumption that DNA alkylation may also be important in human colon cancer formation (10) (11) (12) so that by understanding the mechanisms through which DMH induces colon tumours, new approaches to identifying high risk populations or preventing human colon cancer may be developed.
DMH produces predominantly distal colon tumours but at widely varying rates depending upon the strain of the animal (2) (3) (4) (13) (14) (15) . This differential susceptibility has been ascribed to variations in the ability to metabolize DMH (16, 17) or in proliferative responses to the carcinogen (18) . Furthermore a number of susceptibility loci have been reported including Ccs1 (2), Scc1 and Scc2 (3), Scc3-Scc5 (4) and Scc 6-9 (5) but their biological role remains to be further elucidated. Following DMH administration, susceptible mouse strains can have higher amounts of DNA strand breaks and DNA adducts than non-susceptible strains (19, 20) but such observations are not consistently reported (21, 22) . DNA alkylation is also detected in tissues other than the colon (e.g. liver, kidney) and the specific induction of colon tumours has been ascribed to tissue specific differences in the persistence of certain DNA adducts (21, (23) (24) (25) . Other factors such as whether damaged stem cells, at positions 1 and 2 within the crypt, are selectively removed by apoptosis or suffer deleterious mutations may also be important (26) . Levels of alkyl adducts in DNA in colon tissue are higher in the areas where colon tumours subsequently appear (27) though intra-colonic differences in baseline proliferative parameters (crypt length, labelling index and proliferative zone) have also been reported and are associated with the tumour formation (27, 28) . Such potential risk factors have been examined in model systems in which tumour induction is modified by various agents. Reduced tumour incidence has generally been associated with either reduced adduct levels (e.g. 25) , decreases in cellular proliferation (e.g. 29, 30) or increases in apoptosis (e.g. 29). However, it has also been reported that increased proliferation can be associated with decreased tumour induction (e.g. 31) , that tumour yield can be reduced without a reduction in cell proliferation (32) and that cell proliferation can be reduced without a decrease in tumour incidence (33) . DMH-induced tumour incidence can also be reduced by supplemental dietary calcium without altering DNA adduct levels, DNA repair activity or cellular proliferation parameters in the rat colon (27) .
Such results are generally, but not totally, consistent with a simple model for the induction of tumours by chemical carcinogens that involves the following factors: (a) the formation of DNA adducts within the target tissue and target cells; (b) the lack of repair of DNA adducts by active repair systems;
at Pennsylvania State University on February 23, 2013 http://carcin.oxfordjournals.org/ Downloaded from (c) a decrease in cell loss due to apoptosis; and (d) a subsequent round of DNA synthesis which results in the fixation of mutations at the sites of DNA adducts that have persisted. To further clarify the respective roles of DNA alkylation, DNA repair and cell proliferation, in inducing colon tumours, levels of the pro-carcinogenic adduct, O 6 -methylguanine (O 6 -MeG) in DNA, the activity of O 6 -alkylguanine-DNA alkyltransferase (MGMT) which repairs O 6 -MeG adducts in DNA, and cell proliferation have been measured within the colon following administration of DMH once weekly for up to 20 weeks. This regimen has been shown to induce tumours within the distal colon but not in the proximal colon (34) .
Materials and methods
Treatment of animals 1,2-DMH.2HCl was dissolved in 0.9% saline containing 1 mM EDTA and 10 mM sodium citrate and the pH adjusted to 6.5 using 0.25 M NaOH. Female SWR mice (8-9 weeks old, purchased from Harlan Olac, Blackthorn, Bicester, UK) were given once weekly i.p. injections of 15 mg 1,2-DMH.2HCl/ kg body weight for either 1, 5, 10 or 20 weeks resulting in total doses of 1,2-DMH of 6.8, 34, 68 and 136 mg/kg respectively. Animal experiments were performed in accordance with the Animals (Scientific Procedures) Act of the UK Parliament, 1986. Groups of five mice were killed 8, 56 and 152 h after the final injection of DMH and the large bowel was removed and divided into thirds (proximal, mid and distal colon). Tissues taken for the measurement of O 6 -MeG levels and MGMT activity were placed in Eppendorf tubes, frozen on dry ice and stored at -20°C until DNA or tissue extracts were prepared. Saline control animals were given weekly i.p. injections of the vehicle, 0.9% (w/v) saline containing 1 mM EDTA and 10 mM sodium citrate (pH 6.5). Control tissues for measurement of O 6 -MeG levels were taken at 8, 56 and 152 h after saline treatment: control tissues for MGMT measurement were taken at 56 h after saline treatment.
To determine the extent of DNA synthesis in separate groups of mice, each mouse received 20 µCi of [ 3 H]thymidine (1 mCi/ml) in PBS in a volume of 0.1 ml by i.p. injection 40 min prior to sacrifice. All animals receiving [ 3 H]-thymidine for cell proliferation studies were killed between 4-6 p.m. to reduce the effect of diurnal variation on this parameter. Tissue samples, from the proximal and distal colon, taken for analysis of DNA synthesis were fixed in 70% (v/v) ethanol overnight before embedding and sectioning.
Quantitation of O 6 -MeG in DNA
The tissue of interest from mice in each group was pooled and the DNA extracted using a phenol-based method. It was then dissolved in buffer I (50 mM Tris-HCl pH 8.3, 1 mM EDTA, 3 mM dithiothreitol). O 6 -MeG levels were then measured in a recombinant human O 6 -alkyl-guanine-DNA alkyltransferase inhibition assay using calf thymus DNA methylated in vitro with N-nitroso-N-[ 3 H]-methylurea ([ 3 H]-methylated CT-DNA) as the substrate (35) .
Quantitation of MGMT activity
Tissue from the mice within each group was pooled, minced finely on ice, resuspended in 1 ml of ice-cold buffer I containing 5 µg leupeptin/ml and 10 µl phenylmethylsulphonylfluoride (50 mM PMSF in ethanol). The sample was sonicated for 3 ϫ 10 s and a further 10 µl PMSF was added to the sample immediately after the final sonication. The extract was then separated from the cell debris by centrifugation at 15 000 g, 4°C for 10 min and the supernatant transferred to a fresh tube on ice; the MGMT activity was then measured immediately using [ 3 H]-methylated CT-DNA as the substrate (36) .
Autoradiography of tissue sections
Paraffin embedded sections (3 µm) were dewaxed in xylene overnight, rehydrated and the slide covered with K5-contact emulsion. After drying, the slides were placed in double light-tight boxes containing silica gel, and exposed at 4°C for 10 days before developing. Sections were counterstained with haematoxylin and eosin. Intact longitudinal sectioned crypts with a lumen were counted: 200 half crypts (40 from each of five mice per group) were scored as labelled or unlabelled beginning at the base of the crypt and ending at the lumen of the colon. Cells with more than five grains over the nuclei were considered to be positively [ 3 H]thymidine-labelled.
Data analysis
The time and dose-dependent variation in O 6 -MeG levels and MGMT activity were analysed using ANOVA followed by Dunnett's test. Data generated from tissue autoradiography was analysed by the CRYPTS program written by Dr . 56 h; j 152 h. O 6 -MeG levels did not vary significantly with total DMH dose (P ϭ 0.36) but were associated with time after final treatment (P ϭ 0.02: 8 h vs. 152 h P ϭ 0.01) and with tissue (P Ͻ 0.001: distal colon vs. proximal colon or mid colon P ϭ 0.001 and P ϭ 0.029 respectively).
S.Roberts (Biomathematics and Computing Unit, PICR) which provides the percentage labelling index (i.e. the number of labelled cells divided by the total number of cells; %LI) and LI distribution curves (presented smoothed over three cell positions). Time and dose-dependent variations in labelling index were analysed using ANOVA followed by Dunnett's test after calculating the percentage increase in labelling index, i.e. the difference in mean labelling indices following treatment with DMH or saline divided by the control saline labelling index.
To examine associations between subsequent tumour induction and cumulative changes in potential risk factors, the cumulative sums of (i) O 6 -MeG levels (CSUM O6-MeG ); (ii) the difference between MGMT levels in treated and untreated animals (CSUM MGMT ); and (iii) the difference between labelling indices in treated and untreated animals (CSUM CPI ) and more specifically within crypt cell positions 1 and 2 were calculated in two stages. At each experimental time point (i.e. 1, 5, 10 or 20 weeks which were equivalent to total DMH doses of 6.8, 34, 68 and 136 mg/kg), the area under the curve (AUC) was determined from the change in the variable with the time since the last injection. For MGMT (AUC MGMT ) and cell proliferation indices (AUC CPI ) the time period examined was 0-152 h whereas for O 6 
Results
Associations between biomarkers and DMH exposure O 6 -MeG levels in DNA. O 6 -MeG levels were generally highest in the distal colon, lower in the mid colon and lowest in the proximal colon following DMH injections for up to 20 weeks (Figure 1) . O 6 -MeG levels in the proximal colon at 8, 56 and 152 h after the last DMH dose ranged between 0.7-1.8, 0.2-0.9 and 0.3-0.5 fmol O 6 -MeG/µg DNA ( Figure 1A ). In the mid-colon, O 6 -MeG levels ranged between 4.3-8.6, 0.4-4.8 colon there was a significant association between O 6 -MeG levels 152 h after the last DMH dose and the total DMH dose (r 2 ϭ 0.97, P ϭ 0.02: Figure 1F) . O 6 -MeG levels decreased with time following the last injection in all treatment groups except for those animals that received the highest dose (136 mg/kg DMH) where the adduct appeared persistent (Figure 1 ). At this high dose, adduct levels in the colon appeared to achieve a steady state, with relative O 6 -MeG levels in the proximal, mid-and distal colon being 1.0, 5.4 and 10.6 respectively. After 6.8 mg/kg DMH, the t 1/2 value for O 6 -MeG levels (i.e. 50% of the 8 h level) was reached after~25-32 h in all regions of the colon. After 34 mg/kg DMH, this was~93-113 h, whereas after 68 mg/kg 530 and 152 h (j-j) after final treatment. Labelling indices over the whole crypt or within positions 1 and 2 were not associated with total DMH dose (P ϭ 0.86 and 0.40 respectively). Labelling index in the whole crypt was associated with time after final treatment (P Ͻ 0.006: 8 h vs. 152 h P ϭ 0.02) and 56 vs. 152 h P ϭ 0.006) and with tissue (P ϭ 0.005). Labelling index in cell positions 1 and 2 was also associated with time after final treatment (P ϭ 0.04: 8 h vs. 152 h P ϭ 0.63) and 56 vs. 152 h P ϭ 0.02) and with tissue (P ϭ 0.02). t 1/2 was~25 h in the proximal colon, 57 h in the mid colon and 96 h in distal colon. In those animals treated with 136 mg/ kg DMH, it was not possible to estimate t 1/2 as O 6 -MeG levels had not fallen to Ͻ50% (of the 8 h level) by 152 h after the final dose. O 6 -alkylguanine DNA alkyltransferase levels. In saline treated SWR mice (controls), colonic MGMT levels were measured over the time period of the study and were found to vary between 0.45-2.09, 0.93-2.53, 0.83-1.65 fmol/µg DNA in the proximal, mid-and distal colon respectively (Figure 2) . Following DMH administration, MGMT activity was lowest at 8 h, but had recovered to pre-treatment levels in most cases by 152 h. In the proximal colon, MGMT activity fell to between 15-100% of the saline control level 8 h after treatment ( Figure 2A ) and recovered to 50% of the control level after a further 15-29 h. In the mid colon, MGMT activity fell to 8-53% of that in the saline control 8 h after treatment ( Figure 2C ) and recovered to 50% of the control after a further 33-54 h (depending on the dose). In the distal colon, MGMT activity fell to 11-27% of the saline control level 8 h after treatment ( Figure 2E ) and recovered to 50% of the control after a further 21-47 h (depending on the dose). There were no associations between total DMH dose and MGMT activity in the proximal ( Figure 2B ), mid ( Figure 2D ) or distal colon ( Figure 2F ).
Cell proliferation
Cell proliferation in the proximal and distal colon was altered by treatment with DMH. The percentage increase in labelling index following treatment with DMH is shown in Figure 3 and this increase varied with time after final treatment but not with total DMH dose or tissue. Specifically, labelling was increased 8 and 56 h after DMH treatment but not 152 h.
The position of labelled cells within the crypt also varied in a time dependent manner (data for 136 mg/kg DMH is shown in Figure 4 ). In the proximal colon, there was initially a general increase in the numbers of labelled cells but there was no expansion of the labelling zone after treatment with 136 mg/kg DMH (at 8 h, Figure 4A ). After 56 h there was no difference in either the numbers of cells or the size of the labelling zone ( Figure 4B ) and by 152 h after DMH treatment, the numbers of labelled cells had decreased to below the control level ( Figure 4C ). In contrast, in the distal colon, treatment with 136 mg/kg DMH resulted in both an increase in the number of labelled cells and an upward shift in the labelling zone that was detectable at both 8 h and markedly at 56 h ( Figure 4D and E) . After 152 h these parameters had returned to levels found in control animals ( Figure 4F ).
Associations between biomarkers and tumour yield
Previously we have shown that in this model distal colon tumours were induced in 26%, 67% and 87% of SWR mice treated with a total cumulative dose of 34, 68 and 136 mg/kg DMH respectively (34) . In the mid colon tumours were induced with cumulative doses of 68 and 136 mg/kg DMH in 24 and 43% of animals respectively and no tumours were detected in the proximal colon (34) . The risk factor data described in the previous section together with additional data derived from these risk factor results (AUC; CSUM), were then used to examine whether subsequent tumour yield was associated with:
1. O 6 -MeG levels at specific time points following DMH treatment as these levels provide a snapshot of the mutagenic 531 potential at any specific time (and would be equivalent to a single adduct measurement in human DNA samples). 2. The cumulative O 6 -MeG sum (CSUM O6-MeG ) as this would be a better marker of total adduct formation (and hence total mutagenic potential) than a single adduct measurement. 3. Basal MGMT levels as these levels would help to determine the extent of repair of O 6 -MeG adducts following the initial DMH dose. 4. Induced MGMT levels as these levels would help to determine the extent of repair of O 6 -MeG adducts at subsequent DMH doses. 5. Cumulative changes in MGMT activity (CSUM MGMT ) as this would provide a better indicator of DNA repair activity (and hence removal of O 6 -MeG) over the time course of the experiment. 6. Cumulative changes in labelling index (CSUM CPI ) as this would provide an indicator of the proliferative changes and hence the potential for mutation fixation over the course of the experiment not only within the whole crypt but also within specific regions of the crypt where stem cells are believed to reside.
Adduct formation and persistence
There was no direct association between tumour formation and the 8 h O 6 -MeG level ( Figure 5A ): similar O 6 -MeG levels (~8 µmol/mol dG) were associated with a tumour yield ranging from 0-70%. Similar results were obtained using the 56 h O 6 -MeG levels (data not shown). At 152 h, O 6 -MeG levels above 1 µmol/mol dG were associated with tumour formation but not in a dose-response manner ( Figure 5B ). In addition, O 6 -MeG levels below this level were not associated with tumour formation except in the mid colon where tumours developed although O 6 -MeG was not detectable 152 h after the final treatment ( Figure 5B ). In the proximal colon, the AUC O6-MeG varied little with increasing DMH dose and was significantly lower than those observed in either the mid or distal colon ( Figure 5C ). In the mid colon, the AUC O6-MeG was constant between a total DMH dose of 34-136 mg/kg ( Figure 5C ). In the distal colon, the AUC O6-MeG were generally higher than those in the mid and proximal colon: the relative AUC values were 1:5:10 for the proximal, mid and distal colon, respectively.
The cumulative sum of the weekly amounts of total O 6 -MeG formed (CSUM O6-MeG ) was associated with tumour yield in both the distal and mid colon ( Figure 5D ). Low CSUM O6-MeG levels (~2-3000 units) were associated with tumours in the distal but not the mid or proximal colon. At higher CSUM O6-MeG levels (Ͼ5000 units), the tumour yield was~50% higher in the distal colon than in the mid colon.
DNA repair capacity
There was no association between tumour yield and basal MGMT levels as MGMT levels in the mid and distal colon of untreated animals varied between 1.2-2.3 and 0.6-3.4 times the level in proximal colon, respectively (data not shown). Induced changes in MGMT activity were then examined by comparing the ratio of MGMT activity in treated mice to that in saline control mice 56 h after the last treatment. There was no clear association between the MGMT treated/MGMT nontreated ratio ( Figure 6A ). There were no associations between this MGMT ratio and subsequent tumour yield ( Figure 6B ): the MGMT ratio in the distal colon was higher after treatments which induced tumours but this inverse association was nonsignificant (r 2 ϭ 0.78; P ϭ 0.12: Figure 6B ). The cumulative difference in MGMT levels (CSUM MGMT ) between treated and control animals is shown in Figure 6C . In the distal colon, there was a non-linear association between CSUM MGMT and tumour yield and the greater the CSUM MGMT level the higher the tumour yield but there was no such association in the mid colon ( Figure 6C ). Furthermore, comparable CSUM MGMT levels, which were associated with the formation of tumours in the mid and distal colon, were also found in the proximal colon where no tumours were produced ( Figure 6C ).
Cell proliferation
The AUC CPI for the distal and proximal colon derived from all cell positions or specifically from cell positions 1 and 2 (derived from Figure 4 ) are shown in Figure 7 . AUCs CPI were not associated with total DMH dose but were associated with time after final treatment and with location (i.e. distal or proximal colon).
There was a clear association between CSUM CPI in the distal colon derived from the total labelling index (based on data used in Figure 3 ) and for cell positions 1 and 2 (from Figure 4 ) and subsequent tumour yield (Figure 8 ). Comparable CSUM CPI levels derived from the total labelling index were associated with the formation of tumours in the distal colon but not the proximal colon. However, there was greater discrimination in CSUM CPI levels in cell positions 1 and 2 in that CSUM CPI levels in the proximal colon were at least 50% lower than those associated with tumour formation in the distal colon ( Figure 8B ).
Discussion
Understanding the role of various risk factors in chemical carcinogenesis is clearly of critical importance in identifying populations at increased cancer risk (37) . Increasingly, DNA from different human tissues has been shown to contain DNA adducts, arising both from exogenous and endogenous exposures to chemical carcinogens (38) . These adducts are present in widely different amounts and have widely differing toxic, mutagenic and carcinogenic potential. The biological significance of these adduct levels remains to be clarified but potentially, individuals with high DNA adduct levels may be at increased cancer risk. So far, there is little evidence to support this hypothesis directly from human studies, although individuals with high levels of urinary aflatoxin-guanine adducts were at increased liver cancer risk compared with individuals with low levels (39) .
Associations between DNA adduct levels and tumour induction have been observed in experimental models in which carcinogens are administered chronically to rodents, though the precise nature of this relationship can vary (40) . To further evaluate the relative biological importance of DNA adduct formation, we treated mice with DMH, a known colon carcinogen, over a prolonged period. This model, in principle, mimics the chronic exposures that humans may encounter (41) and we have examined the colonic levels of a putative risk factor (O 6 -MeG) and two risk modifying factors (MGMT activity and cell proliferation indices). Consistent with previous studies (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) , DMH treatment resulted in (i) the formation of O 6 -MeG in colonic DNA in a time and location specific manner; (ii) a concomitant loss in colonic MGMT activity with subsequent recovery; and (iii) marked transient alterations (both increases and decreases) in total cell labelling and positional cell labelling in both the proximal and distal colon.
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We then investigated whether such changes were associated with subsequent tumour induction within the same region of the colon. Individual measurements of DNA damage, induced or basal DNA repair activity or cell proliferation were not in general associated with tumour induction. Persistent (steady state) levels of DNA damage (i.e. O 6 -MeG levels 152 h post treatment) were generally higher in regimes that induced tumours but there was no dose-response relationship. Hence a single measurement of target tissue DNA damage may bear little association to subsequent risk. This may also be the situation for human studies where adduct levels may not be in steady state and can be measured in non-target tissues.
In contrast to these individual measurements, cumulative estimates of total O 6 -MeG levels and cell proliferation indices, particularly within crypt cell positions 1 and 2, where stem cells are believed to reside, were associated with tumour induction in the distal colon. These results are then consistent with an increased cancer risk arising from a higher mutational load due to increased adduct formation/persistence and increased cell proliferation amongst the stem cell population. However other factors, not measured in this study, are also of importance. Increased cell death (e.g. through apoptosis) could explain the lack of linearity in the (cumulative) dose-response curves, observed in the distal colon (42, 43) . Such mechanisms could also potentially explain the difference in tumour yield despite similar cumulative O 6 -MeG levels in the distal and mid colon.
